The removal from plasma of chylomicrons and remnants is reduced in heterozygous familial hypercholesterolemia subjects with identified LDL receptor mutations: Study with artificial emulsions

Imagem de Miniatura
Citações na Scopus
Tipo de produção
Data de publicação
Título da Revista
ISSN da Revista
Título do Volume
ATHEROSCLEROSIS, v.221, n.1, p.268-274, 2012
Projetos de Pesquisa
Unidades Organizacionais
Chylomicron remnants bind to both their specific receptors (LRP) and to the LDL receptor (LDLR) in the liver. There is controversy whether disturbances of chylomicron metabolism occur in subjects with familial hypercholesterolemia (FH). The aim of this study was to evaluate whether there are defects on the removal from plasma of chylomicrons and their remnants in heterozygous FH patients with determined LDLR mutations. We studied 20 heterozygous FH patients (43.2 +/- 12 years old, 60% males) and 50 normolipidemic subjects matched for age and gender. FH subjects were not in use of LDL-lowering drugs for at least 6 weeks. The removal from plasma of chylomicrons and their remnants was measured by isotopic decay after venous injection of a chylomicron-like emulsion radiolabeled with C-14-cholesteryl ester (C-14-CE) and H-3-triolein (H-3-TO). These track respectively removal from plasma of chylomicrons and remnants and lipolysis. There was a significant reduction in the fractional catabolic rates (FCR in h(-1)) of C-14-CE in FH in comparison with normolipidemics: 0.048 (1.46.10-7; 0.57) vs. 0.71(0.049; 1.62), [median (25th-75th percentile)], p = 0.003. No differences were found in FCR of H-3-TO between FH and controls, respectively 1.62 (1.02; 2.331) and 1.914 (1.34; 2.878), p = 0.405. In conclusion heterozygous FH subjects had a significant decrease on the removal from plasma of chylomicrons and their remnants compared with normolipidemics.
Familial hypercholesterolemia, Chylomicrons, Triglyceride-rich lipoproteins, LDL receptor mutations, Emulsions
  1. BOWLER A, 1991, BIOCHEM J, V276, P381
  2. Cabezas MC, 1998, J INTERN MED, V244, P299
  3. Cesar TB, 2006, J NUTR, V136, P971
  4. CHOI SSY, 1991, J CLIN INVEST, V88, P1173, DOI 10.1172/JCI115419
  5. Civeira F, 2004, ATHEROSCLEROSIS, V173, P55, DOI 10.1016/j.atherosclerosis.2003.11.010
  6. Cooper AD, 1997, J LIPID RES, V38, P2173
  7. CUMMINGS MH, 1995, ATHEROSCLEROSIS, V113, P79, DOI 10.1016/0021-9150(94)05430-Q
  8. Dietschy JM, 1998, J NUTR, V128, p444S
  10. HAYASHI H, 1990, AM J PHYSIOL, V259, pG709
  11. HERZ J, 1995, P NATL ACAD SCI USA, V92, P4611, DOI 10.1073/pnas.92.10.4611
  12. HUSSAIN MM, 1995, J BIOL CHEM, V270, P8578
  13. KITA T, 1982, P NATL ACAD SCI-BIOL, V79, P3623, DOI 10.1073/pnas.79.11.3623
  14. LOSSOW WJ, 1969, J LIPID RES, V10, P68
  15. Mamo JCL, 1998, ATHEROSCLEROSIS, V141, pS63, DOI 10.1016/S0021-9150(98)00220-2
  16. Mamo JCL, 1998, EUR J CLIN INVEST, V28, P379
  17. Maranhao RC, 1996, ATHEROSCLEROSIS, V126, P15, DOI 10.1016/0021-9150(96)05889-3
  18. Marchese SRM, 1998, J RADIOANAL NUCL CH, V232, P233, DOI 10.1007/BF02383745
  19. Millar JS, 2005, ARTERIOSCL THROM VAS, V25, P560, DOI 10.1161/01.ATV.0000155323.18856.a2
  20. MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
  21. Proctor SD, 1998, EUR J CLIN INVEST, V28, P497
  22. REDGRAVE TG, 1987, J LIPID RES, V28, P473
  23. REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1
  24. REDGRAVE TG, 1985, BIOCHIM BIOPHYS ACTA, V835, P104, DOI 10.1016/0005-2760(85)90036-0
  25. REIHNER E, 1990, NEW ENGL J MED, V323, P224, DOI 10.1056/NEJM199007263230403
  26. Rensen PCN, 1997, J LIPID RES, V38, P1070
  27. RUBINSZTEIN DC, 1990, J CLIN INVEST, V86, P1306, DOI 10.1172/JCI114839
  28. Santos RD, 2000, AM J CARDIOL, V85, P1163, DOI 10.1016/S0002-9149(00)00721-9
  29. Santos RD, 2001, CARDIOVASC RES, V49, P456, DOI 10.1016/S0008-6363(00)00274-1
  30. Soska V, 2011, CLIN CHIM ACTA, V412, P920, DOI 10.1016/j.cca.2011.01.017
  31. Sposito AC, 2003, ATHEROSCLEROSIS, V166, P311, DOI 10.1016/S0021-9150(02)00334-9
  32. Sposito AC, 2004, ATHEROSCLEROSIS, V176, P397, DOI 10.1016/j.atherosclerosis.2004.05.023
  33. Sposito AC, 2002, ATHEROSCLEROSIS, V161, P447, DOI 10.1016/S0021-9150(01)00661-X
  34. Sposito AC, 2004, J AM COLL CARDIOL, V43, P2225, DOI 10.1016/j.jacc.2003.11.065
  35. Sposito AC, 2001, ATHEROSCLEROSIS, V154, P455, DOI 10.1016/S0021-9150(00)00491-3
  36. Tremblay AJ, 2004, ATHEROSCLEROSIS, V172, P367, DOI 10.1016/j.atherosclerosis.2003.11.011
  37. Twickler TB, 2000, ARTERIOSCL THROM VAS, V20, P2422
  38. Watts GF, 2001, ATHEROSCLEROSIS, V157, P519, DOI 10.1016/S0021-9150(01)00534-2
  39. WILLIAMS RR, 1993, AM J CARDIOL, V72, P171, DOI 10.1016/0002-9149(93)90155-6